SCHEMBL3018886

SCHEMBL3018886

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
TRPV4 Q9HBA0 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR7 P34969 1/20 0.41
TP53 P04637 2/20 0.41
PKM P14618 1/20 0.39
THRB P10828 1/20 0.39
ALOX12 P18054 1/20 0.39
LPAR1 Q92633 1/20 0.39
LPAR2 Q9HBW0 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007463 0.94 ALDH1A1 (0.52) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL15671705 0.93 MAPT (0.46) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3003625 0.91 GAA (0.42) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3002804 0.91 MAPT (0.45) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3018943 0.91 CYP3A4 (0.44) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3008949 0.90 HTR7 (0.44) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3007865 0.89 GAA (0.49) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3014572 0.89 ACLY (0.46) MAPTLMNATSHRALDH1A1POLB
SCHEMBL3014969 0.89 TP53 (0.46) MAPTLMNATSHRALDH1A1KDM4E
SCHEMBL3015393 0.88 ALDH1A1 (0.54) MAPTLMNATSHRALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.